Five year retrospective survival analysis of triple negative breast cancer in North-West India.
Indian J Cancer
;
2013 Oct-Dec; 50(4): 330-332
Article
in English
| IMSEAR
| ID: sea-154305
ABSTRACT
Background:
In our institute, about 10% of total cancer is female breast cancer. This analysis was performed to check triple negativity among these patients with their survival strength up to 5 years in relation to different age groups, stage and chemotherapy protocols. Materials andMethods:
208 immunohistochemistry proved triple negative breast cancer patients registered and treated until 2008 were retrospectively selected for the study. Overall survival up to 5 years was observed on the basis of stage, different age groups and chemotherapy regimens. All patients had undergone surgery, conventional external beam radiation therapy and adjuvant chemotherapy. The survival analyses were performed using the Kaplan-Meier method.Results:
The majority of patients (41%) were in the age group 21-30 years. Stage IV was seen in 18% of the patients at diagnosis and mainly in 21-40 years age group. Only 3% of females were >70 years age and were of Stage I and II. Overall 5 year survival in Stage I in Cyclophosphamide, Adriamycin/Epirubicin, 5-Flurouracil group was 37.5% as compared with Docetaxel/Paclitaxel, Epirubicin group 93% (P < 0.0001).Conclusion:
Triple negativity in North-West India is about 11.8%. We observed it in younger patients mainly with highly aggressive behaviors. Taxane based chemotherapy gives better result as compared with anthracycline based regimens in all stages.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Aged
/
Humans
/
Survival Rate
/
Retrospective Studies
/
Adult
/
Young Adult
/
Triple Negative Breast Neoplasms
/
India
Type of study:
Practice guideline
/
Observational study
Country/Region as subject:
Asia
Language:
English
Journal:
Indian J Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS